1. Home
  2. TLSI vs SPKL Comparison

TLSI vs SPKL Comparison

Compare TLSI & SPKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • SPKL
  • Stock Information
  • Founded
  • TLSI 2010
  • SPKL 2021
  • Country
  • TLSI United States
  • SPKL United States
  • Employees
  • TLSI N/A
  • SPKL N/A
  • Industry
  • TLSI Medical Specialities
  • SPKL
  • Sector
  • TLSI Health Care
  • SPKL
  • Exchange
  • TLSI Nasdaq
  • SPKL Nasdaq
  • Market Cap
  • TLSI 166.8M
  • SPKL 170.5M
  • IPO Year
  • TLSI N/A
  • SPKL 2023
  • Fundamental
  • Price
  • TLSI $4.67
  • SPKL $10.48
  • Analyst Decision
  • TLSI Strong Buy
  • SPKL
  • Analyst Count
  • TLSI 3
  • SPKL 0
  • Target Price
  • TLSI $12.67
  • SPKL N/A
  • AVG Volume (30 Days)
  • TLSI 77.7K
  • SPKL 28.5K
  • Earning Date
  • TLSI 11-12-2024
  • SPKL 01-01-0001
  • Dividend Yield
  • TLSI N/A
  • SPKL N/A
  • EPS Growth
  • TLSI N/A
  • SPKL N/A
  • EPS
  • TLSI N/A
  • SPKL 0.12
  • Revenue
  • TLSI $24,736,000.00
  • SPKL N/A
  • Revenue This Year
  • TLSI $61.24
  • SPKL N/A
  • Revenue Next Year
  • TLSI $47.32
  • SPKL N/A
  • P/E Ratio
  • TLSI N/A
  • SPKL $85.90
  • Revenue Growth
  • TLSI 67.75
  • SPKL N/A
  • 52 Week Low
  • TLSI $3.32
  • SPKL $10.07
  • 52 Week High
  • TLSI $10.42
  • SPKL $11.35
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 36.08
  • SPKL 65.94
  • Support Level
  • TLSI $4.43
  • SPKL $10.45
  • Resistance Level
  • TLSI $5.32
  • SPKL $10.49
  • Average True Range (ATR)
  • TLSI 0.36
  • SPKL 0.00
  • MACD
  • TLSI -0.04
  • SPKL 0.00
  • Stochastic Oscillator
  • TLSI 18.49
  • SPKL 81.63

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About SPKL Spark I Acquisition Corp.

Spark I Acquisition Corp is a Blank check company.

Share on Social Networks: